Brief: Ligand Pharmaceuticals Q3 EPS USD -0.39
07/11/2024 12:00
Nov 07 (Reuters) - Ligand Pharmaceuticals Q3 operating income USD 3.143 million. * Q3 pretax profit USD -6.339 million * Q3 net income continuing operations USD -7.172 million * Q3 basic EPS USD -0.39
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan